Topical bimatoprost in the treatment of eyelash loss in alopecia totalis and universalis: A prospective, open-label study

Jan Ricar, Petra Cetkovska, Maria Hordinsky, Renata Ricarova

Research output: Contribution to journalArticlepeer-review

Abstract

Bimatoprost is a synthetic prostaglandin structural analogue used among other indications to increase eyelash growth. The aim of this prospective, open-label study was to evaluate the safety and efficacy of topical bimatoprost in the treatment of eyelash loss in alopecia areata totalis (AT) and universalis (AU). Study subjects applied ophthalmic bimatoprost (0.3 mg/ml) solution to the eyelid margins once nightly for at least 12 weeks (mean treatment period was 30.6 weeks). A total of 16 out of 17 subjects completed the study. Only the subjects with eyelashes present at baseline experienced an increase in eyelash length and thickness. No new eyelash regrowth was induced. In patients with AT and AU topical bimatoprost affected existing eyelashes, but failed to induce regrowth of new eyelashes.

Original languageEnglish (US)
Article numbere15438
JournalDermatologic therapy
Volume35
Issue number6
DOIs
StatePublished - Jun 2022

Bibliographical note

Funding Information:
Ministry of Education Youth and Sports of the Czech Republic, Grant/Award Number: CZ.02.1.01/0.0/0.0/16_019/0000787 Funding information

Publisher Copyright:
© 2022 Wiley Periodicals LLC.

Keywords

  • alopecia areata
  • alopecia totalis
  • alopecia universalis
  • bimatoprost
  • eyelashes

Fingerprint

Dive into the research topics of 'Topical bimatoprost in the treatment of eyelash loss in alopecia totalis and universalis: A prospective, open-label study'. Together they form a unique fingerprint.

Cite this